The Institute of Bioorganic Chemistry offers customers kits for the detection of genetic markers of risk for developing common human diseases under a manufacturing agreement, mutation detection services under an outsourcing agreement, and is looking for partners interested in a distribution services agreement.

Reagent kits have been developed to detect genetic markers associated with the development of widespread diseases in humans.

Six reagent kits have been developed as medical devices that allow the detection of 60 markers of predisposition to a number of endocrine (obesity, type 2 diabetes, atherosclerosis, etc.) and cardiovascular (thromboembolism, thrombosis, preeclampsia, ischemic stroke, etc.) diseases.

The kits are based on fragment analysis and mini-sequencing methods (SNaPshot analysis technology) with polymerase chain reaction and subsequent fluorescent detection of the resulting fragments.


Information is posted in  Album of promising developments of the NAS of Belarus organizations for the real sector of the economy (2023), p. 181-182. (in Russian)

Own production allows us to supply the required number of kits in a short time, and there is ongoing technical support from the manufacturer.

The kits are adapted for screening studies of citizens of the Union State, as they allow us to analyze genetic markers that are better than others (according to the results of the Union State program "DNA Identification") in identifying predisposition to a number of endocrine and cardiovascular diseases.

All kits have successfully passed clinical trials, according to the results of which registration certificates were received from the Ministry of Health of the Republic of Belarus.

The kits use the principle of multiplexing, which allows us to simultaneously analyze from 5 to 11 markers in one reaction. The required amount of DNA for analysis is 10 ng per reaction.

The use and application of the kits do not pose any environmental risks.

The technologies developed for the production of reagent kits are protected as a commercial secret.

Currently, the Institute of Bioorganic Chemistry of the National Academy of Sciences of Belarus is one of the well-known scientific centers for the study of the most important biopolymers (proteins, enzymes, nucleic acids) and low-molecular bioregulators (steroid hormones of humans, insects and plants, peptides, phospholipids, prostaglandins and their synthetic analogues).

Main areas of activity:
- fundamental and applied research in the field of chemistry, structure and function of biopolymers and low-molecular bioregulators, including proteins, nucleic acids and their components, phospholipids, steroids, prostaglandins, brassinosteroids, ecdysteroids;
- development and pilot production of immunochemical and molecular biological reagent kits for medical and veterinary diagnostics;
- development and production of pharmaceutical substances, hormonal drugs and biospecific hemosorbents;
- development of technologies for the production and use of growth stimulants and plant protection products;
- experimental and clinical pharmacology, pharmacy and drug technology, toxicology, human and animal biochemistry, biomedical and pharmaceutical chemistry;
- preclinical, bioequivalent and pharmaceutical testing.

Main research areas:
- organic and bioorganic chemistry of low-molecular bioregulators (steroids, peptides, prostaglandins, lipids, nucleosides and nucleotides) and the most important biopolymers, including proteins and nucleic acids, establishing patterns of their functioning in living systems;
- development of new chemical, chemical-enzymatic and genetic engineering methods for obtaining biopolymers and low-molecular bioregulators and their analogues in order to create drugs for medicine and agriculture on their basis;
- study of the structure, physicochemical properties and biological activity of natural biomolecules and their analogues, establishing the relationship between their structure and biological activity, development of scientific principles for targeted search for substances with predictable biological activity;
- study of the structure, function and mechanism of action of enzyme systems of biosynthesis and metabolism of the most important natural bioregulators and xenobiotics;
- development of technologies for the production of reagents for medical diagnostics, drugs and chemical plant protection products.

The institute has an experimental base for studying the biological activity of the obtained compounds at the cellular level and in tests on animal models. For the pilot production of the developed products (hemosorbents, recombinant enzyme preparations, immunochemical reagents, oxyphytosterols, etc.), the institute has created 5 pilot production sites.

The results of fundamental and applied research on methods and means of plant protection against diseases, insects, weeds and other adverse environmental factors that are safe for humans and the biosphere as a whole served as the foundation for developing methods for obtaining new plant growth stimulants, pheromone compositions (pheromones of the codling moth LP-U and the miller moth), active ingredients of pesticides (analogues of the herbicide Grasp and the insecticide Confidor), preparative forms of pesticides (herbicides, insecticides, fungicides, etc.).

The created intellectual property of the Institute today consists of valid patents, laboratory technological and pilot-industrial regulations, technical specifications, and trademarks. There are license agreements in force for the transfer of technologies for the production of immunodiagnostic products, hemosorbents and pesticides to manufacturers.

The Institute of Bioorganic Chemistry successfully develops international relations in the main areas of its research. Currently, the institute conducts joint research with scientific institutes in the CIS countries, Germany, the USA, Canada, Sweden, Finland, Denmark, Holland, Vietnam and other countries.

Consumers interested in purchasing kits for the detection of genetic markers of risk for developing common human diseases under a manufacturing agreement, and mutation detection services under an outsourcing agreement.

Partners interested in purchasing kits for the detection of genetic markers of risk for developing common human diseases under a distribution services agreement.